A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Sponsor: Eli Lilly and Company
This PHASE1 trial investigates Obesity and Overweight and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .